← Retension Pharmaceuticals, Inc. (RTSN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Retension Pharmaceuticals, Inc. (RTSN)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-03-15 (est.)Phase 2 · RTN-001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SLx-2101 | Phase 2 | Hypertension |
| RTN-001 | Phase 2 | Uncontrolled Hypertension |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RTSN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.